Prevalence and Predictors of Appropriate Colorectal Cancer Surveillance in Lynch Syndrome
Elena M. Stoffel(University of Michigan), Sapna Syngal(Dana-Farber Cancer Institute), Rowena Mercado(Dana-Farber Cancer Institute), Peggy Conrad(University of California, San Francisco), Kristen M. Shannon(Massachusetts General Hospital), Wendy Kohlmann(University of Utah), Stephen B. Gruber(University of Southern California), Daniel C. Chung(Icahn School of Medicine at Mount Sinai), Jonathan P. Terdiman(UCSF Helen Diller Family Comprehensive Cancer Center), Beth Ford(Dana-Farber Cancer Institute), Amie Blanco(University of California, San Francisco), Mark Powell(Dana-Farber Cancer Institute), Shilpa Grover(Brigham and Women's Hospital)
Cited by 71
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k